Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia

Launched by UNIVERSITY OF GENEVA, SWITZERLAND · Aug 22, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how genetic factors influence the treatment response and side effects in Indian children with acute lymphoblastic leukemia (ALL), a common type of cancer in kids. The research aims to understand why some children experience more severe side effects from chemotherapy and how their genetics might affect the effectiveness of steroid treatments. The study is being conducted in India and Switzerland, with a focus on gathering information from children aged 1 to 18 who are newly diagnosed with ALL and have not received any treatment before.

To participate, children must be of Indian origin and fit specific treatment guidelines. They will undergo regular check-ups and provide samples for genetic testing to help researchers learn more about how different genes may influence their treatment outcomes. Families can expect close monitoring and support throughout the study, and all participants will need consent from a parent or guardian to take part. This research could ultimately help improve treatment plans and reduce side effects for children fighting leukemia.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age \> 1 year old and ≤18 years old at enrolment
• • Previously untreated
• • ALL diagnosis confirmed by morphology and flow-cytometry
• • Indian origins
• • Fulfilling IciCle treatment protocol inclusion criteria and receiving treatment as per the protocol
• • Written Informed consent to participate in the study has to be signed by the participant/parent/guardian
• Exclusion Criteria:
• • Previously tretaed patients
• • Patients with Down's syndrome
• • Patients with mature B-ALL